**NEW TOPIC Prevention of Cardiovascular Disease in the Medicare Population
The Symposium is free and open to all ISPOR delegates, no pre-registration required.
This session will describe an application of the Archimedes Model to analyze the morbidity, mortality, and cost of CVD in the Medicare population and the effects of 16 different strategies for preventing CVD. The interventions include aspirin, smoking cessation, weight loss, and blood pressure, cholesterol, and glucose control. Results will be presented in the form of an “annual report” – Medicare can expect to see each year over the next 30 years, taking into account the changes in demographics over that period. The presentation will include an explanation of how the Archimedes Model represents populations, physiological and diseases, care processes, the effects of interventions, behaviors, and financial costs.
Speaker: David Eddy PhD, MD Founder & Medical Director, Archimedes, San Francisco, CA, USA
HEALTH CARE POLICY DEVELOPMENT USING OUTCOMES RESEARCH
W8: ARE WE BETTER OFF OR WORSE OFF WITH VALUE-BASED PURCHASING (VBP)? Discussion Leaders: Peter K. Wong PhD, MBA, MS, RVP, Quality, Clinical Effectiveness & Chief Pharmacy Officer, Clincial Effectiveness Mercy Health Partners, Southwest Ohio, Cincinnati, OH, USA; Dennis J Hanseman PhD, Senior Health Researcher, Clincial Effectiveness Mercy Health Partners, Southwest Ohio, Cincinnati, OH, USA; Alan H Mutnick PharmD, FASHP, Director, Clincial Effectiveness Mercy Health Partners, Southwest Ohio, Cincinnati, OH, USA
W9: CONSIDERATION OF CLINICAL AND ECONOMIC VALUE IN U.S. HEALTH TECHNOLOGY ASSESSMENT: A MULTIPLE STAKEHOLDER VIEW Discussion Leaders: Daniel A. Ollendorf MPH, Chief Review Officer, Institute for Clinical & Economic Review, Boston, MA, USA; Steven D. Pearson MD, MSc, Senior Fellow, America's Health Insurance Plans, Washington, DC, USA; Amy Knudsen PhD, Senior Scientist, Massachusetts General Hospital, Institute for Technology Assessment, Boston, MA, USA
PATIENT-REPORTED OUTCOMES RESEARCH
W10: SELECTING, EVALUATING AND DOCUMENTING SUPPORT FOR EXISTING INSTRUMENTS FOR MAKING LABELING CLAIMS: CONTENT VALIDITY Discussion Leaders: Pennifer Erickson PhD, Founder, OLGA, State College, PA, USA; Nancy Leidy PhD, Senior Vice President Scientific Affairs, United BioSource Corporation, Bethesda, MD, USA; Charles D Petrie PhD, Senior Director/Group Leader, Neurosciences, Pfizer, Global Outcomes Research, Groton, CT, USA; Margaret Rothman PhD, Senior Director, WW Patient Reported Outcomes Center of Excellence, Johnson & Johnson Pharmaceutical Services, LLP, Washington, GA, USA
W11: METHODS FOR MEDICATION COMPLIANCE STUDIES: AN OVERVIEW OF THE ISPOR MEDICATION COMPLIANCE SIG GUIDELINES Discussion Leaders: Elizabeth Manias MPharm, PhD, Associate Professor, University of Melbourne, School of Nursing and Social Work, Faculty of Medicine, Dentistry and Health Sciences, Carlton, Victoria, Australia; Femida Gwadry-Sridhar BScPhm, MSc, PhD, Assistant Professor, University of Western Ontario, Depts. of Medicine and Physiology & Pharmacology, London, ON, Canada; Joshua S. Benner PharmD, ScD, Principal, IMS Health, Inc, Health Economics and Outcomes Research, Falls Church, VA, USA; Andrew M. Peterson PharmD, Chair, Department of Pharmacy Practice and Pharmacy Administration, University of the Sciences in Philadelphia, Pharmacy Practice and Pharmacy Administration, Philadelphia, PA, USA
USE OF REAL WORLD DATA
W12: ECONOMIC DATABASES FOR PHARMACOECONOMIC EVALUATIONS IN CANADA: OVERVIEW AND USE Discussion Leaders: Carl V. Asche PhD, Research Associate Professor, University of Utah College of Pharmacy, Outcomes Research Center, Department of Pharmacotherapy, Salt Lake City, UT, USA; Philip Jacobs DPhil, Director, Institute of Health Economics, Edmonton, AB, Canada; Rita Yim MA, MHSA, Research Fellow, Institute of Health Economics, Edmonton, AB, Canada; Joanne Kingston PhD, Senior Economist, Institute of Health Economics, Edmonton, AB, Canada
W15: AN UNBIASED OVERVIEW AND UNDERSTANDING OF THE USE OF PROPENSITY SCORING IN PHARMACOECONOMIC AND PHARMACOEPIDEMIOLOGY RESEARCH Discussion Leaders: Matthew W. Reynolds PhD, Managing Director, Epidemiology and Database Services, United BioSource Corporation, Medford, MA, USA; Christopher Hollenbeak PhD, Assistant Professor, Penn State College of Medicine, Health Evaluation Sciences, Hershey, PA, USA; David J. Vanness PhD, Assistant Professor, University of Wisconsin-Madison, Department of Population Health Sciences School, Madison, WI, USA
HEALTH CARE POLICY DEVELOPMENT USING OUTCOMES RESEARCH
W18: EFFECTIVELY COMMUNICATING OUTCOMES RESEARCH TO ENHANCE PRODUCT SUCCESS Discussion Leaders: Allen Lising HBA, Managing Director, Dymaxium Inc, Consulting Division, Toronto, ON, Canada; Deborah Marshall PhD, Vice President, i3 Innovus, Global Health Economics and Outcomes, Burlington, ON, Canada; Eric Nauenberg PhD, University of Toronto, Toronto, ON, Canada
W19: TRANSPARENT AND QUANTIFIABLE APPROACHES TO HEALTH CARE DECISION MAKING: CHALLENGES AND OPPORTUNITIES FOR MULTI CRITERIA DECISION ANALYSIS (MCDA) Discussion Leaders: Mireille M Goetghebeur PhD, VP Operations, BioMedCom Consultants Inc, Montreal, QC, Canada; Louis Niessen MD, PhD, Senior Researcher, Erasmus Medical Center, Institute for Medical Technology Assessment, Rotterdam, The Netherlands; Lonny J Erickson PhD, Senior Associate, Health Technology Assessment, BioMedCom Consultants Inc, Montreal, QC, Canada; Hanane Khoury PhD, Senior Research Application Associate, BioMedCom Consultants Inc, Montreal, QC, Canada
PATIENT-REPORTED OUTCOMES RESEARCH
W20: DEVELOPING AN IMPROVED MEASURE OF HEALTH OUTCOMES: EQ-5D IN TRANSITION Discussion Leaders: Frank De Charro PhD, Senior Scientific Advisor, Pharmerit Europe, Rotterdam, The Netherlands; Paul Kind, Professor, University of York, Outcomes Research Group, York, UK; Ben A. Van Hout PhD, Professor, Pharmerit BV, Rotterdam, The Netherlands; Xavier Badia MD, PhD, PhD, IMS Health, Health Economics and Outcomes, Barcelona, Spain
W22: QUANTITATIVE APPROACHES TO BENEFIT-RISK ASSESSMENT OF PHARMACEUTICALS Discussion Leaders: Lisa McGarry MPH, Director, i3 Innovus, Health Economics & Outcomes Research, Medford, MA, USA; Anju Parthan PhD, Senior Project Manager, i3 Innovus, Health Economics and Outcomes Research, San Francisco, CA, USA
ECONOMIC OUTCOMES RESEARCH
W23: WORKPLACE IMPACT MODEL OF A PHARMACEUTICAL TREATMENT FROM AN EMPLOYER PERSPECTIVE Discussion Leaders: Peter Sun, MD, PhD, Chief Health Economist, Kailo Research Group, Indianapolis, IN, USA; Lizheng Shi, PhD, Assistant Professor, Tulane University, Health Systems Management, New Orleans, LA, USA; Howard Birnbaum PhD, Vice President, Analysis Group, Inc, Boston, MA, USA
W24: ASSESSING PATIENT COSTS FOR CANCER IN THE U.S: HOW, WHO, WHEN, AND WHAT Discussion Leaders: Michael T. Halpern MD, PhD, Strategic Director, American Cancer Society, Health Services Research, Atlanta, GA, USA; K. Robin Yabroff PhD, Epidemiologist, National Cancer Institute, Applied Research Program, Bethesda, MD, USA; Ya-Chen Tina Shih PhD, Associate Professor, University of Texas M.D. Anderson Cancer Center, Department of Biostatistics and Applied Mathematics, Houston, TX, USA
W26: TRAINING CONSIDERATIONS FOR PATIENT-REPORTED OUTCOMES Discussion Leaders: Adam John Butler SR, Assistant Vice-President, Training and Education, United BioSource Corporation, Wayne, PA, USA; Anne M Rentz MSPH, Research Scientist, United BioSource Corporation, The Center for Health Outcomes Research, Bethesda, MD, USA
HEALTH CARE POLICY DEVELOPMENT USING OUTCOMES RESEARCH
W28: REAL-LIFE PATIENT-REPORTED OUTCOMES: A NOVEL USE OF THE FDA ADVERSE EVENT REPORTING SYSTEM (AERS) SAFETY DATABASE Discussion Leaders: Matthew W. Reynolds PhD, Managing Director, Epidemiology and Database Services, United BioSource Corporation, Medford, MA, USA; Donald Stull PhD, Research Scientist, United BioSource Corporation, Center for Health Outcomes Research, Bethesda, MD, USA; Robert Nordyke PhD, MS, Director, Amgen, Inc, Global Health Economics, Thousand Oaks, CA, USA
W29: CAPTURING THE IMPACT OF HETEROGENEITY IN PHARMACOECONOMIC EVALUATION Discussion Leaders: Denis Getsios BA, Research Scientist, United BioSource Corporation, Concord, MA, USA; Kristen Migliaccio-Walle BS, Research Scientist, United BioSource Corporation, Concord, MA, USA; Duygu Bozkaya MSc, MBA, Researcher, United BioSource Corporation, Concord, MA, USA
